MK2-IN-1

MK2-IN-1 (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC50 of 0.11 uM for MK2 and an EC50 of 0.35 uM for pHSP27. MK2-IN-1 impaires the phosphorylation level of serine residues in the Tfcp2l1 protein[1][2].

Product Specifications

CAS Number

[1314118-92-7]

UNSPSC

12352005

Target

HSP; MAPKAPK2 (MK2)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/MK2-IN-1.html

Purity

99.04

Solubility

10 mM in DMSO

Smiles

O=C(C1=CC=C(C2=CC=C(Cl)C=C2)O1)N(C3=CC=C(N4CCNCC4)C=C3)CC5=NC=CC=C5

Molecular Formula

C27H25ClN4O2

Molecular Weight

472.97

References & Citations

[1]Rao AU, et al. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors. Bioorg Med Chem Lett. 2012 Jan 15;22 (2) :1068-72.|[2]Yan Zhang, et al. MK2 promotes Tfcp2l1 degradation via β-TrCP ubiquitin ligase to regulate mouse embryonic stem cell self-renewal. Cell Rep. 2021 Nov 2;37 (5) :109949.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Biol Pharm Bull. 2025;48 (2) :172-176.|Cell Rep. 2021 Nov 2;37 (5) :109949.|J Pharmacol Exp Ther. 2019 Aug;370 (2) :219-230.|Cell Death Dis. 2021 Oct 23;12 (11) :994.|University of Minnesota. 2025.